RxDoctor Payments Data

Jennifer Steinberg

Medical · East Islip, NYNPI 1043265648

Payments from drug & device makers

$2,245in general payments, 2019–2025

Across 102 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$288
  • AstraZeneca$277
  • Novo Nordisk$267
  • Pfizer$212
  • Exact Sciences$188
  • AbbVie$165
  • plus $848 from 17 others

What the payments were for

  • Food & beverage$2,23499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,245 in reported general payments places this provider in the 80th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$195,672
Medicare patients
313
Services billed
4,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$159,800
MounjaroTirzepatide85$128,074
EliquisApixaban39$63,326
XareltoRivaroxaban13$20,118
WegovySemaglutide11$15,464
Breo ElliptaFluticasone/Vilanterol13$9,268
Levothyroxine Sodium185$3,114
Albuterol Sulfate HfaAlbuterol Sulfate89$2,521
Atorvastatin Calcium242$2,261
Metoprolol Succinate156$2,206
Rosuvastatin Calcium200$1,959
Pantoprazole Sodium104$1,186
Omeprazole111$1,016
Losartan Potassium131$1,005
Escitalopram Oxalate105$867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$267$175,264103 claims
Lilly USA, LLCMounjaro$144$128,07485 claims
PfizerEliquis$212$63,32639 claims
GSKBreo Ellipta$55$9,26813 claims
AbbVieSynthroid$165$74415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,395 medical providers in New York.

Other medical in East Islip

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →